Literature DB >> 24157421

Effects of molsidomine against doxorubicin-induced cardiotoxicity in rats.

O M Disli1, E Sarihan, M C Colak, N Vardi, A Polat, J Yagmur, B Tamtekin, H Parlakpinar.   

Abstract

PURPOSE: To explore the protective and curative effects of molsidomine (MOL) on doxorubicin (DOX)-induced cardiac damage in the in vivo rat heart.
METHODS: Forty rats were randomized into five groups (n = 8): (1) the control group; (2) the MOL group (10 mg/kg for 21 days); (3) the DOX group (a single dose of 20 mg/kg); (4) the DOX + MOL group (3 days after the single dose of DOX, 10 mg/kg MOL continued for 21 days), and (5) the MOL + DOX group (24 h after a 21-day regimen of 10 mg/kg MOL, a single dose of DOX). The rats were monitored for mean arterial blood pressure, heart rate, O2 saturation, and electrocardiography. Heart tissue levels of malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH), and nitric oxide (NO) were determined.
RESULTS: Blood pressure and O2 saturation values indicated a significant decrease in the DOX group compared with the control group. T negativity was observed in 4 of 8 rats in the DOX group, in 1 of 8 rats in the DOX + MOL group, and in 4 of 8 rats in the MOL + DOX group. MDA levels were significantly higher in the DOX group. SOD, GSH, and NO levels were significantly lower in the DOX group compared with the other groups. There was no statistically significant difference in the CAT levels in any of the study groups compared with controls. DOX treatment induced morphological alterations, such as disorganization of cardiomyocytes, loss of myofibrils, and cytoplasmic vacuolization in the heart. On the other hand, histological damage was significantly reduced in the DOX + MOL and MOL + DOX groups.
CONCLUSION: This study implies that there are cardioprotective effects of MOL on DOX-induced cardiotoxicity.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24157421     DOI: 10.1159/000354807

Source DB:  PubMed          Journal:  Eur Surg Res        ISSN: 0014-312X            Impact factor:   1.745


  4 in total

1.  Protective and therapeutic effect of molsidomine on bleomycin-induced lung fibrosis in rats.

Authors:  Talat Kilic; Hakan Parlakpinar; Alaadin Polat; Elif Taslidere; Nigar Vardi; Ediz Sarihan; Hilal Ermis; Kevser Tanbag
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

Review 2.  Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.

Authors:  Jing Zhang; Xiaohai Cui; Yan Yan; Min Li; Ya Yang; Jiansheng Wang; Jia Zhang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

3.  The protective role of molsidomine on the Cisplatin-induced ototoxicity.

Authors:  Yuksel Toplu; Hakan Parlakpinar; Emrah Sapmaz; Erkan Karatas; Alaattin Polat; Ahmet Kizilay
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-04-02

Review 4.  Protecting the heart in cancer therapy.

Authors:  J Emanuel Finet; W H Wilson Tang
Journal:  F1000Res       Date:  2018-09-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.